ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 2026 • 2018 ACR/ARHP Annual Meeting

    Calcium Crystal-Mediated Netosis in Juvenile Dermatomyositis and Anti-RNP+ Overlap Syndrome with Skin Involvement

    Christian Lood1, Gabrielle A. Morgan2, Marisa Klein-Gitelman3, Megan L. Curran4 and Lauren M. Pachman5, 1Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, 2Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 3Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 4Section of Rheumatology, Children's Hospital of Colorado, Denver, CO, 5Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

    Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Although beneficial from a…
  • Abstract Number: 2920 • 2018 ACR/ARHP Annual Meeting

    Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis

    Gian Marco Moneta1, Ivan Caiello1, Lucilla Rava'2, Silvia Rosina3, Luisa Bracci Laudiero1,4, Angelo Ravelli3,5, Fabrizio De Benedetti6 and Rebecca Nicolai7, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 2Epidemiology Unit, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 3University of Genova, Genova, Italy, 4Institute of Translational Pharmacology, CNR, Roma, Italy, 5Rheumatology, Giannina Gaslini Institute, Genova, Italy, 6IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 7Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

    Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). We previously reported that expression of both type I…
  • Abstract Number: 776 • 2018 ACR/ARHP Annual Meeting

    MMP7 and CXCL12: Two Promising Biomarkers in Lupus Nephritis

    Sylvie Goletti1,2, Séverine Nieuwland3, Frédéric A. Houssiau2,3 and Bernard R. Lauwerys2,3, 1Service de Microbiologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 3Rheumatology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium

    Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of Systemic lupus erythematosus (SLE). Early diagnosis of renal impairment, combined with a strict…
  • Abstract Number: 1095 • 2018 ACR/ARHP Annual Meeting

    IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus

    Wietske Lambers1, Geert Lanting1, Wayel H. Abdulahad2, Hendrika Bootsma2, Johanna Westra2 and Karina de Leeuw3, 1Rheumatology/Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Incomplete systemic lupus erythematosus (iSLE) includes patients with typical features of SLE, who do not meet classification criteria. Still, up to 50% will develop…
  • Abstract Number: 1521 • 2018 ACR/ARHP Annual Meeting

    Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis

    Sara Remuzgo-Martínez1, Fernanda Genre1, Verónica Pulito-Cueto1, Verónica Mijares1, Leticia Lera-Gómez1, Jaime Calvo-Alén2, Ricardo Blanco1, Oreste Gualillo3, Javier Llorca4, Santos Castañeda5, Raquel Lopez-Mejías1 and Miguel Angel González-Gay1,6,7, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, 3SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 4Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, 5Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, 6Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 7School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain

    Background/Purpose: Leptin is an adipokine that plays an important role in the regulation of body weight and also participates in immune homeostasis and inflammatory processes1,2.…
  • Abstract Number: 2028 • 2018 ACR/ARHP Annual Meeting

    Microwave and Magnetic (M2) Myocardial Proteomics in the Mouse Model of Kawasaki Disease Demonstrates Normalization of the Proteome after Interleukin-1 Inhibition, Potential Novel Biomarkers, and Suggests New Insights into Mechanism of Disease

    Mark Gorelik1, Carol Chase2, Magali Noval Rivas3, Jean Patterson1, Moshe Arditi3 and Thomas Forsthuber2, 1Immunology and Virology, Texas Biomedical Research Institute, San Antonio, TX, 2University of Texas San Antonio, San Antonio, TX, 3Pediatrics, Cedars Sinai, Beverly Hills, CA

    Background/Purpose: Kawasaki disease (KD), a predominantly coronary vasculitis of childhood, remains the most common cause of acquired heart disease of childhood in the developed world,…
  • Abstract Number: 2933 • 2018 ACR/ARHP Annual Meeting

    Non-Invasive Tape Sampling Reveals RNA Gene Clusters in Cutaneous Lupus Erythematosus That Discriminate Affected from Unaffected and Healthy Volunteer Skin

    Joseph F. Merola1, Wenting Wang2, Carrie Wager3, Stefan Hamann2, Xueli Zhang3, Alice Thai2, Chris Roberts2, Christina Lam4, Cristina Musselli2, Galina Marsh2, Dania Rabah2, Catherine Barbey5, Nathalie Franchimont2 and Taylor L. Reynolds2, 1Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Biogen, Cambridge, MA, 3Formerly of Biogen, Cambridge, MA, 4Boston University Medical School, Boston, MA, 5Biogen, Zug, Switzerland

    Background/Purpose: Punch biopsy, the standard diagnostic and monitoring procedure for patients with cutaneous lupus erythematosus (CLE), impedes patient recruitment and follow up due to risk…
  • Abstract Number: 173 • 2017 ACR/ARHP Annual Meeting

    Applying Urine Proteomics for Discovery of Lupus Nephritis Damage Biomarkers in a Pediatric Cohort

    Jessica Turnier1, Bruce Aronow2, Kenneth Greis3, Michael Bennett4, Wendy Haffey3, Sherry Thornton5, Gaurav Gulati6, Michael Wagner7, David Witte8, Prasad Devarajan9 and Hermine I. Brunner10, 1Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Computational Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3University of Cincinnati College of Medicine, Cincinnati, OH, 4Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, 7Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 10Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Non-invasive biomarkers of lupus nephritis (LN) damage are needed to guide treatment decisions and determine risk for kidney failure. Urinary proteomics has advanced as…
  • Abstract Number: 680 • 2017 ACR/ARHP Annual Meeting

    Abnormalities in Complement System Are Related to Disease Severity in Systemic Lupus Erythematosus (SLE)

    Cristina Arriens1, Sonali Narain2, Amit Saxena3, Christopher E. Collins4, Daniel J. Wallace5, Elena Massarotti6, John Conklin7, Roberta Alexander7, Kenneth C. Kalunian8, Chaim Putterman9, Rosalind Ramsey-Goldman10, Jill P. Buyon11, Anca Askanase12, Richard Furie2, Susan Manzi13, Joseph Ahearn14, Arthur Weinstein15 and Thierry Dervieux7, 1Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Northwell Health, Great Neck, NY, 3Rheumatology, NYU Langone Medical Center, New York, NY, 4Rheumatology, MedStar Washington Hospital Center, Washington, DC, 5Cedars-Sinai Medical Center, UCLA, Los Angeles, CA, 6Brigham and Women's Hospital, Boston, MA, 7Exagen Diagnostics, Inc., Vista, CA, 8Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, 9Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, 10FSM, Northwestern University, Chicago, IL, 11Medicine, New York University School of Medicine, New York, NY, 12Rheumatology, Columbia University, New York, NY, 13Medicine, Allegheny Health Network, Pittsburgh, PA, 14Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, 15Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC

    Background/Purpose: We sought to evaluate the relationships between low complement C3 and C4 proteins, abnormal complement activation (cell-bound complement activation products [CB-CAPs]), and a Lupus…
  • Abstract Number: 1010 • 2017 ACR/ARHP Annual Meeting

    Identification of Circulating Biomarkers of Disease Activity and Organ Involvement in ANCA-Associated Vasculitis By Targeted Proteomics

    Jun Ishizaki1, Ayako Takemori2, Koichiro Suemori1, Takuya Matsumoto1, Yoko Akita1, Masaki Yasukawa1, Nobuaki Takemori2 and Hitoshi Hasegawa1, 1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, 2Division of Proteomics Research, Proteo-Science Center, Ehime University, Ehime, Japan

    Background/Purpose: Targeted proteomics, which involves quantitative analysis of targeted proteins using selected reaction monitoring (SRM) mass spectrometry, has emerged as a new methodology for discovery…
  • Abstract Number: 1535 • 2017 ACR/ARHP Annual Meeting

    Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment

    Mireia Moreno1, Caridad Pontes2, Ferran Torres3, Agusti Sellas-Fernandez4, Miriam Almirall5, Juan Carlos Torre-Alonso6, Teresa Clavaguera7, Carlos Rodriguez-Lozano8, Luis Francisco Linares9, Ana Urruticoechea-Arana10, Eduardo Collantes-Estevez11, Rosa Morla12, Delia Reina13, Eduardo Cuende14, Pedro Zarco15, Cruz Fernandez-Espartero16, Rosario García-Vicuña17, Jesus Sanz18, Xavier Juanola19, Antoni Vallano20, Francisco J Blanco21, Raimon Sanmarti22, Gonzalo Calvo23, Cristina Avendaño24, Eugenio De Miguel25, Roser Vives26, Raul Veroz Gonzalez27, Carlos Alberto Montilla-Morales28 and Jordi Gratacos-Masmitja29, 1Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, 2Clinic Pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, 3Hospital Clinic de Barcelona, Barcelona, Spain, 4Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, 5Rheumatology, Hospital del Mar, Barcelona, Spain, 6H Monte Naranco, Oviedo, Spain, 7Rheumatology. Palamós Hospital, Rheumatologist, Catalonia, Spain, 8Rheumatology, Hospital Universitario Dr. Negrin, Gran Canaria, Spain, 9Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 10Rheumatology Department. Hospital Can Misses, IBIZA, Spain, 11Rheumatology, IMIBIC-Hospital Universitario Reina Sofia, Cordoba, Spain, 12Rambla Vella, 14, Hospital La Tecla, Tarragona, Spain, 13Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 14University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, 15H Fundación Alcorcón, Alcorcón, Spain, 16Rheumatology, Hospital de Mostoles, Madrid, Spain, 17Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 18Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 19Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 20Clinic pharmacology, Hospital Universitari Bellvitge, Barcelona, Spain, 21Servicio de Reumatología. Area Genomica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, 22Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, 23Clinic pharmacology, Hospital Clinic Barcelona, Barcelona, Spain, 24Clinic pharmacology, Hospital Puerta de Hierro, Madrid, Spain, 25Medicine, Universidad Autonoma Madrid, MADRID, Spain, 26Clinic pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, 27Hospital de Mérida, Mérida, Spain, 28Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 29Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Barcelona, Spain

    Background/Purpose: Some clinical guidance recommends empirical TNFi dose reductions in AS patients despite lack of robust supportive evidence. Recently, we communicated that a strategy of…
  • Abstract Number: 2322 • 2017 ACR/ARHP Annual Meeting

    Quantitative Proteomics Comparison of Children with Inactive and Active Uveitis

    Sheila Angeles-Han1, Duc Duong2, Steven Yeh3, Purnima Patel4, Virginia Miraldi Utz5, Kirsten Jenkins6, Danielle Lowe7, Sampath Prahalad8 and Gary Holland9, 1Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, 2Emory University, Atlanta, GA, 3Ophthalmology, Emory University School of Medicine, Atlanta, GA, 4Emory University School of Medicine, Atlanta, GA, 5Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, 6Children's Healthcare of Atlanta, Atlanta, GA, 7Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, 9Jules Stein Eye Institute, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Children with chronic non-infectious uveitis are at high risk for sight-threatening complications and vision loss. No biomarker predicts uveitis development or treatment response. Aqueous…
  • Abstract Number: 2875 • 2017 ACR/ARHP Annual Meeting

    Molecular Features Define Unique Sjögren’s Syndrome Patient Subsets

    Judith A. James1, Joel M. Guthridge2, Hua Chen3, Rufei Lu3, Rebecka L. Bourn3, Alan N. Baer4, Ghaith Noaiseh5, Anne Parke6, Andreea Coca7, Tammy Utset8, Mark C. Genovese9, Teresa Aberle3, Daniel J. Wallace10, Karen Boyle11, Lynette Keyes-Elstein12, Nathalie Franchimont13, Eugene St. Clair14, Virginia Pascual15, Paul J. Utz16 and Kathy L. Sivils2, 1Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 5University of Pittsburgh Medical Center, Pittsburgh, PA, 6University of Connecticut, Farmington, CT, 7University of Rochester Medical Center, Rochester, NY, 8University of Chicago, Chicago, IL, 9Stanford University Medical Center, Palo Alto, CA, 10UCLA, Beverly Hills, CA, 11Rho Federal Systems, Inc, Chapel Hill, NC, 12Rho Federal Systems, Inc., Chapel Hill, NC, 13Biogen, Cambridge, MA, 14Department of Medicine, Duke University Medical Center, Durham, NC, 15Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX, 16Medicine, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: Immunologic heterogeneity in primary Sjogren’s syndrome (pSS) poses a challenge when selecting a therapeutic for a given patients or when assembling patient cohorts for…
  • Abstract Number: 179 • 2017 ACR/ARHP Annual Meeting

    Mass Spectrometry Imaging of Synovium: A Novel Approach to Classify the Rheumatoid and Psoriatic Arthritis Patients

    Beatriz Rocha1,2, Berta Cillero-Pastor3, Gert Eijkel3, Lennart R. Huizing3, Cristina Ruiz-Romero1,4, Andrea Cuervo5,6, Ron M A Heeren3, Juan D. Cañete5,6 and Francisco J Blanco1,6, 1Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, A Coruña, Spain, A Coruña, Spain, 2The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands, Masstricht, Netherlands, 3The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands, Maastricht, Netherlands, 4CIBER-BBN Instituto de Salud Carlos III, INIBIC-CHUAC, A Coruña, Spain., A Coruña, Spain, 5Arthritis Unit, Rheumatology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain, Barcelona, Spain, 6RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain

    Background/Purpose: Psoriatic arthritis (PsA) and Rheumatoid arthritis (RA) are immune-mediated chronic inflammatory diseases. Synovial membrane is the initial site of inflammation in PsA and RA…
  • Abstract Number: 681 • 2017 ACR/ARHP Annual Meeting

    A Panel of Lupus Biomarkers for the Monitoring of Systemic Lupus Erythematosus: Performance Characteristics in Distinct SLE Cohorts

    Joan T. Merrill1, Thierry Dervieux2, Jill P. Buyon3, Rosalind Ramsey-Goldman4, Kenneth C. Kalunian5, Chaim Putterman6, John Conklin2, Richard Furie7 and Michelle Petri8, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Exagen Diagnostics, Inc., Vista, CA, 3Medicine, New York University School of Medicine, New York, NY, 4FSM, Northwestern University, Chicago, IL, 5Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, 6Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, 7Northwell Health, Great Neck, NY, 8Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD

    Background/Purpose: Antibody titers to double stranded DNA (anti-dsDNA) and complement C3 and C4 proteins have clinical utility in the routine monitoring of systemic lupus erythematosus…
  • « Previous Page
  • 1
  • …
  • 71
  • 72
  • 73
  • 74
  • 75
  • …
  • 109
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology